ClinicalTrials.gg
RecruitingNCT07207824HEROUpdated Jul 21, 2026

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

A Phase 3 interventional study of Active Comparator: BCG induction and maintenance and DV + BCG induction and maintenance in Bladder (Urothelial, Transitional Cell) Cancer and NMIBC, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Primary conditionNon-Muscle Invasive Bladder NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Muscle Invasive Bladder Neoplasms
Why
  1. The study's listed conditions name Non-Muscle Invasive Bladder Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms — 6 open to participants now, 12 under way, 5 of them phase 3. BCG Vaccine · Non-Muscle Invasive Bladder Neoplasms.

Planned enrollment
8th of 17
182 · median 160
Started
2025
with 3 others
Phase 3
6 of 17
2 open now
Primary completion
2030-06
later than 10 of 11 live
Registered
16th of 17
by date
Lead sponsor
1 of 17
Fudan University

Among the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, this one is the 8th largest by planned enrollment, is one of 4 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 10 of the 11 other live ones, and was the 16th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

6 of the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About BCG Vaccine

BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine (Disitamab Vedotin) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk. Each participant was assigned to one of two study treatment groups: One group is given Disitamab Vedotin and BCG.The second group is given BCG only and will not receive Disitamab Vedotin.

Read the detailed description

HERO: A Phase III Randomized Controlled Trial of Disitamab Vedotin (DV) Combined with Bacillus Calmette-Guérin (BCG) in BCG-Naïve Patients with HER2-Expressing, High-Risk Non-Muscle-Invasive Bladder Cancer

This Phase 3, open-label, randomized, controlled clinical trial will enroll approximately 182 patients, who will be assigned in a 1:1 ratio to one of two treatment groups:

Group A: Disitamab Vedotin plus BCG (induction and maintenance therapy)

Group B: BCG alone (induction and maintenance therapy)

The study is designed to demonstrate the superiority of Disitamab Vedotin combined with BCG (during both induction and maintenance phases) over BCG alone in prolonging event-free survival (EFS) among BCG-naïve participants with high-risk, HER2-expressing non-muscle invasive bladder cancer.

03

Conditions studied

  • Bladder (Urothelial, Transitional Cell) Cancer
  • NMIBC

Browse trials for

Keywords

  • NMIBC
  • disitamab vedotin
  • HER2
  • BCG
04

In context

Non-Muscle Invasive Bladder Neoplasms Reclassified

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

This study's planned enrollment of 182 is above the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Lead sponsor

Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.

Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. confirmed high-risk, non-muscle-invasive urothelial carcinoma of the bladder (UCC) (with >50% urothelial carcinoma as the predominant histological component), defined by the presence of any of the following: a. T1 tumor; b. High-grade Ta tumor; c. Carcinoma in situ (CIS).
  3. Complete resection of all Ta/T1 papillary lesions (including patients with concomitant CIS). The most recent Transurethral Resection of Bladder Tumor (TURBT) must have been performed within 12 weeks prior to randomization. A second TURBT was required if indicated per current local applicable guidelines.
  4. expression (IHC 1+/2+/3+) as confirmed by immunohistochemistry (IHC) testing at the local institution's pathology department.
  5. Unwillingness or ineligibility to undergo radical cystectomy.
  6. (ECOG) performance status (PS) of ≤ 2.
  7. Signed form (ICF).

Exclusion criteria

Exclusion Criteria

  1. confirmed evidence of muscle-invasive (T2 or higher), locally advanced, or urothelial carcinoma, or the presence of concurrent extravesical non-muscle-invasive urothelial carcinoma.
  2. Histopathological findings of pure small cell carcinoma, pure adenocarcinoma, pure squamous cell carcinoma, or pure squamous CIS of the bladder.
  3. History of upper tract urothelial carcinoma (except for cases with no recurrence within 2 years following radical treatment for UTUC).
  4. Prior therapy with any other type of -targeted inhibitor.
  5. Major surgery within 2 weeks prior to randomization.
  6. Any other condition that, in the investigator's judgment, would make the patient unsuitable for participation in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    DV + BCG

    Disitamab Vedotin + BCG induction and maintenance

    Drug: DV + BCG induction and maintenance

  • Active comparator
    BCG

    BCG induction and maintenance

    Drug: Active Comparator: BCG induction and maintenance

Interventions

  • DrugActive Comparator: BCG induction and maintenance

    Drug page: BCG VaccineStudies of BCG VaccineBCG Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: Bacillus Calmette-Guerin Immunotherapy treatment approved by NMPA for patients with high-risk non-muscle invasive bladder cancer Other Names: BCG

  • DrugDV + BCG induction and maintenance

    Drug page: BCG VaccineStudies of BCG VaccineBCG Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: Disitamab vedotin(RC48) •An antibody-drug conjugates (ADCs) targeting HER2, has been approved in China for chemotherapy-refractory advanced UC with HER2-expression. Other Names: • RC48, DV Drug: Bacillus Calmette-Guerin Immunotherapy treatment approved by NMPA for patients with high-risk non-muscle invasive bladder cancer Other Names: BCG

07

What researchers measure

Primary outcomes

  1. Event free survival

    Event free survival is defined as the time from randomization to date of EFS event.

    Time frame: 55 months after first participant randomized

Secondary outcomes

  1. Overall Survival

    Overall survival is defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Randomization up to 60 months from last participant randomized

  2. Complete response rate at 6m/12m in participants with CIS at randomization

    Complete response (CR) rate defined as the proportion of participants in the analysis population with CR.

    Time frame: Randomization up to 12 months from last participant randomized

  3. Disease-specific survival

    Disease specific survival (DSS) is defined as the time from randomization to death resulting from bladder cancer.

    Time frame: Randomization up to 60 months from last participant randomized

  4. Health-related quality of life as measured by EORTC QLQ-C30

    Health-related quality of life as measured by EORTC QLQ-C30

    Time frame: Randomization up to 60 months from last participant randomized

  5. Health-related quality of life as measured by EORTC QLQ-NMIBC24

    EORTC-QLQ-NMIBC24 has 24 items which can be grouped into 6 subscales: urinary symptoms (7 items), malaise (2 items), future worries (4 items), bloating/flatulence (2 items), sexual functioning (2 items), and male sexual issues (2 items). The NMIBC24 also assesses intravesical treatment, female sexual issues, sexual intimacy, risk of contaminating a partner, and sexual enjoyment (1 item each).

    Time frame: Randomization up to 60 months from last participant randomized

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — Individual Participant Data is protected.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Jun 2030, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Oct 6, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Jun 1, 2030
CompletionEst.
Dec 1, 2030
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07207824
Lead sponsor
Fudan University
Responsible party
Ding-Wei Ye (Director of Urology, Fudan University) — Principal investigator
First posted
Oct 6, 2025
Start date
Dec 1, 2025
Primary completion
Jun 1, 2030 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Jul 21, 2026

Study contacts

Yi jun Shen, M.D.
Contact
yijunshen@urocancer.org
862164175590

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BCG Vaccine

Start the discussion